Potential Antibacterial Application of Cannabinoids: A Narrative Review of Preclinical Studies

Aaliyah Caupain, Aleksi Hupli

Tutkimustuotos: ArtikkeliProfessional


Every year, an estimated 700,000 to 1.27 million individuals die of infection with microorganisms that have acquired resistance to antimicrobial therapy, such as methicillin-resistant Staphylococcus aureus (MRSA). As part of the search for new antimicrobial treatments, there is interest in the potential antibacterial properties of cannabinoids. This narrative review aims to summarize the current preclinical evidence regarding the antibacterial properties of cannabinoids.
The review was conducted in December 2021 using an electronic search performed on PubMed and Google Scholar with appropriate keywords and without language or time restrictions. Studies that did not involve the purification and separation of cannabinoids were excluded. Nine available studies met the eligibility criteria.
These studies found that cannabinoids, especially delta-9-tetrahydrocannabinol, cannabidiol, and cannabinol, have promising antibacterial effects, including against S. aureus and MRSA. Certain cannabinoids were also able to increase the antibacterial effect of conventional antibiotics against gram-negative bacteria. However, clinical trials are needed, and the pharmacologic profiles of cannabinoids should be better understood.
Cannabinoids have a promising future as antimicrobial agents. However, further clinical investigation is needed regarding their mechanism of action in vivo and in human trials, particularly looking at their function in human serum and blood.
JulkaisuThe American Journal of Endocannabinoid Medicine
TilaJulkaistu - 31 lokak. 2023
OKM-julkaisutyyppiD1 Artikkeli ammattilehdessä


Sukella tutkimusaiheisiin 'Potential Antibacterial Application of Cannabinoids: A Narrative Review of Preclinical Studies'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Siteeraa tätä